A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases
BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence. This study aims to analyze and compare adverse drug r...
Sparad:
| Huvudupphov: | , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2025-04-01
|
| Serie: | Frontiers in Pharmacology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1561020/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|